Edge Pharmacy Services Expands Manufacturing Operations In Colchester, Vermont
04/04/2017
According to company officials, “Edge specializes in a wide variety of compounded pharmaceuticals with specific focuses in operating room anesthesia, medications for ophthalmic surgery, dermatology, ENT, and allergy treatment. As demand for its products continues to increase, Edge is addressing the long term solution and investing over $1.5 million into expanding production capacity. The new capabilities implemented during the expansion will increase production capacity by 5 times what it is today.”
“With the new FDA and state 503B Outsourcing laws, the pharmaceutical industry is in a transitional period, since it is no longer legal to purchase many medications from traditional compounding pharmacies for office or hospital use,” officials explained. “This is precipitating a large increase in the need for FDA registered and inspected facilities capable of keeping up with the demand."
Included in Edge's expansion plan is the introduction of robotics into the manufacturing processes. Typically reserved for traditional pharmaceutical manufacturing, bringing industrial automation to the 503B Outsourcing space is a critical step to providing customers with not only the necessary throughput, but the assurance that quality and repeatability are built into the basic operations of the manufacturing process.
Edge officials said introducing robotics will allow the company to keep pace with the production demands, while also passing along the benefits of economies of scale to its customers in the form of reduced costs. Like any other industry, as volumes increase the justification for automation becomes easier, which in turn results in lower costs for the customer. It is very typical for Edge not only to bring hospitals and surgery centers into compliance with these new regulations, but also save them hundreds of thousands of dollars per year in pharmaceutical costs.
With respect to regulation, Edge noted “several changes over the past 3 years have impacted health care providers. Edge has been diligent in complying with new rules and regulations implemented by the Boards of Pharmacy, the Food and Drug Administration, USP-795, and USP-797. In the last 3 years, Edge has completed two FDA inspections and 7 Board of Pharmacy inspections, each very closely looking at and commenting on its processes in manufacturing and quality control.”
Project Announcements
United Kingdom-Based Risk Ledger Plans Rockville, Maryland, Operations
04/03/2026
Umbra Plans Reston, Virginia, Engineering-Production Operations
04/03/2026
Associated Wholesale Grocers Expands Pearl River, Louisiana, Distribution Operations
04/02/2026
Brazil-Based TSEA Energy Plans Eden, North Carolina, Manufacturing Operations
04/02/2026
AMAROK Plans Columbia, South Carolina, Headquarters Operations
04/02/2026
Belgium-Based UCB Plans Gwinnett County, Georgia, Manufacturing Operations
04/01/2026
Most Read
-
Top States for Doing Business in 2024: A Continued Legacy of Excellence
Q3 2024
-
Economic Developer Role Shifting from Deal-Making to Systems Stewardship
Q1 2026
-
What Companies Need from Modern Manufacturing Sites
Q1 2026
-
Capitalizing on the OBBBA Before the 2026 Cliff
Q1 2026
-
Last Word: Don’t Lose by Winning
Q1 2026
-
Advanced Manufacturing Isn’t a Buzzword—It’s a Different Location Strategy
Q1 2026
-
The Geography of Packaging: Why Location Strategy Matters More Than Ever
Q1 2026